Godavari Biorefineries Ltd

Godavari Biorefineries announced that its European patent for a novel anti-cancer molecule has been validated in Spain, the United Kingdom, and as a Unitary Patent covering multiple EU member states. This milestone underscores the company's growing presence in high-impact scientific innovation, led by its dedicated Anti-Cancer Research Segment. The patented molecule has demonstrated efficacy against both cancer cells and cancer stem cells, marking a promising advance toward more targeted and effective cancer therapies. It has shown potential in the treatment of various cancers, including breast and prostate cancer, with encouraging efficacy and safety profiles in preclinical animal studies. The molecule is currently in Phase 1a clinical trials to assess safety in human patients with advanced solid tumors as well as in healthy volunteers. Powered by Capital Market - Live

Net profit of Godavari Biorefineries rose 10.37% to Rs 71.93 crore in the quarter ended March 2025 as against Rs 65.17 crore during the previous quarter ended March 2024. Sales declined 5.80% to Rs 579.50 crore in the quarter ended March 2025 as against Rs 615.19 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 23.41 crore in the year ended March 2025 as against net profit of Rs 12.30 crore during the previous year ended March 2024. Sales rose 10.88% to Rs 1870.25 crore in the year ended March 2025 as against Rs 1686.67 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales579.50615.19 -6 1870.251686.67 11 OPM %19.4018.50 -5.547.92 - PBDT108.58104.87 4 48.5272.37 -33 PBT95.7490.98 5 -1.5412.45 PL NP71.9365.17 10 -23.4112.30 PL Powered by Capital Market - Live

Godavari Biorefineries will hold a meeting of the Board of Directors of the Company on 24 May 2025.Powered by Capital Market - Live

Net profit of Godavari Biorefineries declined 85.01% to Rs 5.76 crore in the quarter ended December 2024 as against Rs 38.43 crore during the previous quarter ended December 2023. Sales rose 12.37% to Rs 447.27 crore in the quarter ended December 2024 as against Rs 398.02 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales447.27398.02 12 OPM %8.0711.25 - PBDT20.8128.83 -28 PBT8.4712.76 -34 NP5.7638.43 -85 Powered by Capital Market - Live

Godavari Biorefineries will hold a meeting of the Board of Directors of the Company on 8 February 2025.Powered by Capital Market - Live

Godavari Biorefineries has announced an investment in grain/corn-based ethanol to further strengthen its ethanol production capabilities. The company plans to invest approximately Rs 130 crore in a new 200 KLPD corn/grain-based distillery to its existing operations, enhancing flexibility through dual-feedstock capability. The company reported a 25% Y-O-Y increase in revenue growth in H1FY25, demonstrating its operational strength and focus on sustainable growth. Key Highlights of the Investment: '' Proposed Capacity: 200 KLPD Corn/grain-based distillery. '' Investment Required: Approximately Rs 130 crore. '' Mode of Finance: Internal accruals and debt. '' Commissioning Timeline: Q4 FY 2026 Powered by Capital Market - Live

This partnership grants GBL exclusive rights to leverage Catalyxx's technology for the conversion of ethanol to for up to 30,000 tons of biobutanol and other higher alcohols in India and selling globally. Godavari will in the first phase, construct and operate a facility designed to produce 15,000 metric tons of biobutanol and higher alcohols annually. Catalyxx Inc. is a leading company in sustainable chemistry. Catalyxx is dedicated to replacing the use of fossil-based chemicals and committed to transform the industry making it greener, more efficient and sustainable. Samir Somaiya, chairman and managing director (CMD) of GBL, said: 'This partnership with Catalyxx Inc reflects our commitment to advancing sustainable chemistry and underscores our leadership in the bio-chemicals sector. We are excited to embark on this journey and look forward to the positive impact this project will have on our business, the environment, and the communities we serve.' Godavari Biorefineries is an integrated sugar company operating in sugar, power, industrial alcohol and specialty chemicals. Powered by Capital Market - Live

Revenue from operations declined 33.73% YoY to Rs 320.05 crore in the quarter ended 30 September 2024. The company reported pre tax loss of Rs 64.11 crore in Q2 FY25 as compared with pre tax loss of Rs 65.14 crore reported in same period last year. During the quarter, EBITDA loss stood at Rs 31.53 crore in Q2 FY25 as against an EBITDA loss of Rs 30.61 crore recorded in Q2 FY24. EBITDA margin came in at 9.8% in Q2 FY25 as against negative EBITDA margin of 12.7% registered in the same period a year ago. The firm reported a negative net profit margin of 23.3% in Q2 FY25 as against negative 27.1% registered in similar quarter previous fiscal. On the segmental front, revenue from sugar was at Rs 170.87 crore in Q2 FY25, spiked 137.88% year on year. Biobased Chemicals revenue was at Rs 10.17 crore (up 79.04% YoY), distlliery revenue was at Rs 31.36 crore (down 34.36% YoY) during the period under review. Commenting on the Results, Samir Somaiya, CMD said, - 'Firstly, I would like to extend my heartfelt thanks to all our new shareholders for placing their trust in us andcontributing to the success of our IPO. We are committed to building a sustainable business and creating longterm value for all our stakeholders. As you may know, our business is subject to seasonality due to the sugarcane harvesting period, whichtypically runs from November to March. Consequently, our performance in the first half of the financial yeartends to be weaker compared to the second half. With the government's reinstatement of the EthanolBlending Program from sugarcane juice, GBL is poised to leverage its enhanced capacity, and we anticipateseeing its impact starting from Q3 FY25 onwards. A large portion of the IPO proceeds will be utilized to repay debt amounting to Rs 240 crore, enhancing ourbalance sheet strength and generating sufficient free cash flow to support further expansion within our biobased chemicals segment. This initiative will also improve profitability through interest cost savings. Weremain optimistic about the growth prospects of our bio-based chemicals segment and the green energytransition, and we are focused on expanding in these areas'. Godavari Biorefineries is one of the larger producers of ethanol and a pioneer in manufacturing ethanolbased chemicals in India. Its diversified product portfolio comprises bio-based chemicals, sugar, rectified spirits, ethanol, other grades of alcohol and power. It is the only company in India to have such a vast portfolioof bio-based products such as MPO, natural 1,3 butylene glycol, ethyl vinyl ether and other bio-basedchemicals.Powered by Capital Market - Live

Net Loss of Godavari Biorefineries reported to Rs 75.00 crore in the quarter ended September 2024 as against net loss of Rs 65.15 crore during the previous quarter ended September 2023. Sales rose 34.11% to Rs 320.95 crore in the quarter ended September 2024 as against Rs 239.31 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales320.95239.31 34 OPM %-10.16-13.18 - PBDT-51.81-50.15 -3 PBT-64.11-65.15 2 NP-75.00-65.15 -15 Powered by Capital Market - Live

Godavari Biorefineries will hold a meeting of the Board of Directors of the Company on 18 November 2024Powered by Capital Market - Live